Literature DB >> 24951867

AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection.

Yu-Na Lee1, Min-Chul Kim2, Young-Tae Lee1, Hye Suk Hwang1, Min-Kyoung Cho1, Jong Seok Lee1, Eun-Ju Ko1, Young-Man Kwon1, Sang-Moo Kang3.   

Abstract

The ectodomain of matrix protein 2 (M2e) of influenza virus is suggested to be a rational target for a universal influenza A vaccine. However, there are some concerns that M2e vaccines might not be highly effective in the general population with diverse genetic backgrounds. Here we examined the immunogenicity and protective efficacy of the baculovirus-derived virus-like particles containing multiple M2e (M2eVLP) with AS04 adjuvant in a C57BL/6 mouse strain (H-2(b)). M2eVLP vaccine induced significant levels of M2e-specific IgG in C57BL/6 mice after vaccination. Furthermore, M2eVLP adjuvanted with AS04 was more effective than M2eVLP alone in conferring protection as well as in inducing recall humoral and T cell responses specific for M2e after lethal influenza virus challenge. A mechanistic study provides evidence that activation of dendritic cells by the toll-like receptor 4 agonist MPL in the AS04 adjuvant was associated with interferon-γ producing CD4 T cell responses. Our results suggest that AS04 adjuvanted M2eVLP vaccines have the potential to improve cross-protection.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adjuvants; C57BL/6; Influenza virus; M2e VLPs

Mesh:

Substances:

Year:  2014        PMID: 24951867      PMCID: PMC4126506          DOI: 10.1016/j.vaccine.2014.06.040

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Safe Recombinant Outer Membrane Vesicles that Display M2e Elicit Heterologous Influenza Protection.

Authors:  Hannah C Watkins; C Garrett Rappazzo; Jaclyn S Higgins; Xiangjie Sun; Nicole Brock; Annie Chau; Aditya Misra; Joseph P B Cannizzo; Michael R King; Taronna R Maines; Cynthia A Leifer; Gary R Whittaker; Matthew P DeLisa; David Putnam
Journal:  Mol Ther       Date:  2017-02-16       Impact factor: 11.454

2.  Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.

Authors:  Eun-Ju Ko; Young-Tae Lee; Ki-Hye Kim; Youri Lee; Yu-Jin Jung; Min-Chul Kim; Yu-Na Lee; Taeuk Kang; Sang-Moo Kang
Journal:  J Immunol       Date:  2016-11-23       Impact factor: 5.422

3.  A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.

Authors:  Wandi Zhu; Winston Pewin; Chao Wang; Yuan Luo; Gilbert X Gonzalez; Teena Mohan; Mark R Prausnitz; Bao-Zhong Wang
Journal:  J Control Release       Date:  2017-06-19       Impact factor: 9.776

4.  Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity.

Authors:  Min-Chul Kim; Yu-Na Lee; Hye Suk Hwang; Young-Tae Lee; Eun-Ju Ko; Yu-Jin Jung; Min Kyoung Cho; Yu-Jin Kim; Jong Seok Lee; Suk-Hoon Ha; Sang-Moo Kang
Journal:  Vaccine       Date:  2014-08-27       Impact factor: 3.641

5.  Adjuvant effects of killed Lactobacillus casei DK128 on enhancing T helper type 1 immune responses and the efficacy of influenza vaccination in normal and CD4-deficient mice.

Authors:  Yu-Jin Jung; Ki-Hye Kim; Eun-Ju Ko; Youri Lee; Min-Chul Kim; Young-Tae Lee; Cheol-Hyun Kim; Subbiah Jeeva; Bo Ryoung Park; Sang-Moo Kang
Journal:  Vaccine       Date:  2020-07-13       Impact factor: 3.641

6.  Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.

Authors:  Vladimir Beljanski; Cindy Chiang; Greg A Kirchenbaum; David Olagnier; Chalise E Bloom; Terianne Wong; Elias K Haddad; Lydie Trautmann; Ted M Ross; John Hiscott
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

7.  Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.

Authors:  Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Yu-Jin Kim; Jongsang Lee; Cheol Kim; Suk-Hoon Ha; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2015-08-04       Impact factor: 5.970

8.  Multimeric recombinant M2e protein-based ELISA: a significant improvement in differentiating avian influenza infected chickens from vaccinated ones.

Authors:  Farshid Hadifar; Jagoda Ignjatovic; Simson Tarigan; Risa Indriani; Esmaeil Ebrahimie; Noor Haliza Hasan; Andrea McWhorter; Sophie Putland; Abdulghaffar Ownagh; Farhid Hemmatzadeh
Journal:  PLoS One       Date:  2014-10-16       Impact factor: 3.240

9.  Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.

Authors:  Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Sang-Moo Kang
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

Review 10.  M2e-Based Universal Influenza A Vaccines.

Authors:  Lei Deng; Ki Joon Cho; Walter Fiers; Xavier Saelens
Journal:  Vaccines (Basel)       Date:  2015-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.